Abiopharma

Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

RxSight, Inc. Reports Second Quarter 2025 Financial Results

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

New Form SCHEDULE 13G/A - Phio Pharmaceuticals Corp. Filed: 2025-08-07 AccNo: 0001641172-25-022581 Size: 7 KB

New Form 6-K - Ascendis Pharma A/S Filed: 2025-08-07 AccNo: 0001193125-25-175420 Size: 146 KB

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology Reports Second Quarter 2025 Financial Results

iSpecimen to Establish $200M Corporate Treasury Built Around Solana Cryptocurrency with BlockArrow

10x Genomics - 10x Genomics Reports Second Quarter 2025 Financial Results

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update